Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14504645 | 0.83 | TDP1 (0.44) | TDP1ALDH1A1CYP2D6EPHX1CYP3A4 | |
| SCHEMBL2000699 | 0.81 | — | — | |
| SCHEMBL18380898 | 0.78 | TDP1 (0.68) | TDP1TSHRALDH1A1CYP2D6EPHX1 | |
| SCHEMBL8596242 | 0.74 | TDP1 (0.76) | TDP1ALDH1A1CYP2D6EPHX1PLG | |
| SCHEMBL8596237 | 0.74 | TDP1 (0.76) | TDP1ALDH1A1CYP2D6EPHX1PLG | |
| SCHEMBL14504650 | 0.74 | CTSL (0.55) | KDM4E | |
| SCHEMBL4697448 | 0.74 | TDP1 (0.83) | TDP1ALDH1A1CYP2D6EPHX1CYP3A4 | |
| SCHEMBL13999422 | 0.74 | TDP1 (0.83) | TDP1ALDH1A1CYP2D6EPHX1CYP3A4 | |
| SCHEMBL7296108 | 0.73 | TDP1 (0.82) | TDP1TSHRCYP2D6EPHX1ALOX5 | |
| SCHEMBL7296555 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485632-B2 | Cephalosporins | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2009-02-03 | — | — | US | disclosed |
| EP-1529050-B1 | CEPHALOSPORINS | SANDOZ AG (CH) | 2006-05-24 | — | — | EP | disclosed |
| US-20050234233-A1 | e.g. 3-{(E)[[1-trans-(4-Amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl}-7- {[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino}-3-cephem-4-carboxylic acid; microbiocide; Escherichia, Enterobacter, Enterococcus, Klebsiella, Streptococcus, Staphylococcus and Pseudomonas | NABRIVA THERAPEUTICS AG (AT) | 2005-10-20 | — | — | US | disclosed |
| EP-1529050-A1 | CEPHALOSPORINS | Sandoz AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004007505-A1 | CEPHALOSPORINS | SANDOZ AG (CH) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234233-A1 | e.g. 3-{(E)[[1-trans-(4-Amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl}-7- {[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino}-3-cephem-4-carboxylic acid; microbiocide; Escherichia, Enterobacter, Enterococcus, Klebsiella, Streptococcus, Staphylococcus and Pseudomonas | CD14, GNE, ECH1 | TDP1 4317/4885TSHR 4164/4885ALDH1A1 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.